BUSINESS
Why have MFs fallen in love with Mankind Pharma just a month since its listing?
Put it down to the home advantage, or the company’s strong position in the Indian pharmaceuticals market.
BUSINESS
Top life insurers turn bullish on healthcare stocks; investments higher than sector weightage in Nifty 100
ICICI Prudential Life, Kotak Life, Tata AIA Life, HDFC Life and SBI Life added at least one healthcare stock to their portfolios in May while raising stakes in several others.
BUSINESS
Riches to rags: How the pharma growth story faltered over the decade?
Since delivering outperforming returns from 2010-2015, an era when pharma was the talk of the town, the sector has lost its upward momentum. Six of the past eight years, Nifty Pharma has underperformed Nifty 50.
BUSINESS
Max, Fortis set for robust earnings growth on new CGHS rates: Jefferies
According to the global brokerage, both hospitals get a substantial portion of their sales from patients covered by the subsidised treatment scheme
BUSINESS
KIE sees margin expansion for Sun Pharma despite high R&D spends
The brokerage has an 'add' call for Sun Pharma, with a price target of Rs 1,150 per stock, reflecting an upside potential of 16.5 percent from the closing price on June 8. The company is the brokerage firm's top pick in the pharma sector.
BUSINESS
What are the implications of the govt's ban on 14 fixed-dose combination drugs?
Most analysts do not see the drug ban materially impacting financials for drugmakers.
BUSINESS
Why contract drug manufacturers meet FDA norms easily while others struggle
Contract development and manufacturing organisations undergo several rounds of inspections before they are engaged by client companies to make key drug ingredients.
BUSINESS
Know your stock | Why are analysts upbeat on KIMS?
General Atlantic Singapore sold a 2.89 percent stake in KIMS in a block deal on May 30 for Rs 371.3 crore, grabbing an opportunity offered by a surge in the share price to book a partial profit
BUSINESS
Apollo Hospitals' occupancy to reach 70%, Apollo 24*7 on path to breakeven: MD
Apollo Hospitals will reach its occupancy target by reducing its reliance on institutional patients and increasing focus on international patients, recruitment of more doctors and improving the payor mix.
BUSINESS
Why are brokerages divided over Torrent Pharma’s outlook despite a strong Q4 show?
Many brokerages see margin pressure and expensive valuations impacting the stock while some others are betting on branded business and a steady domestic market to provide a boost.
BUSINESS
Mazagon Dock Shipbuilders surges 5% on robust quarterly show
Mazagon Dock Shipbuilders also recorded its highest ever revenue and net profit for FY23.
BUSINESS
Apollo Hospitals gains 2% on hopes of strong Q4 earnings
Apollo Hospitals' growth in the fourth-quarter is likely to be aided by a favourable base, strong seasonality and better occupancy.
BUSINESS
Sun Pharma Preview: Strong specialty biz, robust domestic sales to boost company’s health in Q4
The company's specialty business is likely to post double-digit growth YoY in the quarter, despite some sequential moderation, according to brokerages.
BUSINESS
Fed officials divided over support for more rate hikes, FOMC meet minutes show
While Fed officials were leaning towards a pause in rate hikes after the May meeting, an end to policy tightening still remains out of question.
BUSINESS
Gland Pharma’s prospects after dismal earnings fail to impress investors
Analysts are also concerned about the lack of optimism in the management's commentary on margins improving.
BUSINESS
Is dual drug filing the right tactic for pharma companies now?
While only two large-cap players have firmed up plans to embark on this route, analysts expect other players too to follow suit, albeit majorly for key drugs, thanks to the gains involved in simultaneously filing for new launches from two sites.
BUSINESS
Delayed drug launches to hurt Cipla’s earnings in FY24
An update by Cipla's management that key drug launches will now be delayed by around 12 months have prompted a slew of earnings downgrades for FY24.
BUSINESS
Expect EBITDA margin to sustain at 25-30% in FY24, says Meghmani Finechem CMD Maulik Patel
Though the China+1 theme has lent greater focus on Indian manufacturing, Patel feels India has quite a distance to cover to catch up with China in this sphere.
BUSINESS
Cipla's Q4 net profit surges 45% on year to Rs 525.65 crore, lags estimate
Cipla's Q4 revenue was largely in-line with the Street's expectations of Rs 5,744.42 crore.
BUSINESS
Closing Bell: Sensex up 123 points, Nifty above 18,330; M&M, IndusInd, Axis Bank top gainers
Closing Bell: Nifty Bank, Auto shines; Metal, Oil & Gas, Pharma falls
BUSINESS
Cipla Q4 preview: Robust domestic traction, gRevlimid sales likely to give earnings a big boost
Cipla Q4 preview: The company is expected to double its consolidated net profit to Rs 723.4 crore from Rs 362.07 crore in the year-ago quarter. It is also seen as the biggest beneficiary of a strong flu season in India
BUSINESS
Dr Reddy's fall 5% even after Q4 net profit jumps 10-fold. Here's why
Despite the huge jump, Dr Reddy's net profit for the fourth quarter lagged Street's estimate and brokerages are concerned about the firm's growth map
BUSINESS
Closing Bell: Indices close marginally lower; Dr Reddy's, L&T, Hindalco, Divi's Lab top losers
Closing bell: Sensex, Nifty close marginally lower. Dr Reddy's, L&T, Hindalco, Divi's Lab top losers while Adani Ent, Asian Paints, HUL top gainers
BUSINESS
Dr Reddy's Q4 net profit jumps to Rs 959 crore on favourable base, US launches, brand deals
Dr Reddy's bottomline also lagged the Street's estimate of Rs 1,093.6 crore.
